GRT 6011Alternative Names: GRT-6011
Latest Information Update: 18 May 2016
At a glance
- Originator Grunenthal
- Class Analgesics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Hypersensitivity; Neuropathic pain
Highest Development Phases
- No development reported Hypersensitivity; Neuropathic pain
Most Recent Events
- 18 May 2016 No recent reports on development identified - Phase-I for Neuropathic pain and Hypersensitivity in Germany (PO)